Hansa Biopharma year-end report Jan-Dec 2020
Commercial launch activities for Idefirix[®] progressing as planned; Patient recruitment in clinical studies reinitiated in December 2020; Company financed into 2023Lund February 4, 2021. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January – December, 2020. Highlights for the fourth quarter 2020 · Commercial launch activities in early launch countries within the European Union are underway as planned. During Q4’20, initial pharmacy level pricing for Idefirix[®] was